About US
Contact us
-
WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threatsNew legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. Thursday, the House Select Committee on the Strate2024/1/18
-
FDA clears penicillin imports from French drugmaker amid Pfizer shortageWith U.S. syphilis cases on the rise and Pfizer’s Bicillin treatment still in short supply, France’s Laboratoires Delbert is stepping in to help with temporary imports. The French drugmaker is workin2024/1/15
-
JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC dealsSanFrancisco—Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates (ADCs). “Building a world-class oncology organization,2024/1/15
-
Regulatory tracker: GSK's severe asthma drug Nucala wins approval in ChinaUPDATED: Thursday, Jan.11 at 10:00 a.m. China'sNational Medical Products Administrationhas approvedGSK's Nucalaas an add-on maintenance treatment for patients with severe eosinophilic asthma who ar2024/1/11
-
JPM24: Bluebird CEO points to 'very innovative contract' to defend Lyfgenia's pricing premium over CRISPR rivalSan Francisco—Bluebird bio’s 40%list-price premiumfor Lyfgenia compared with Vertex and CRISPR Therapeutics’ sickle cell disease drug surprised many industry watchers last month. But bluebird CEO And2024/1/11
-
JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030With a late-stage pipeline spanning more than 120 clinical trialsand a firm grasp offive major disease areas, AstraZeneca appears confident heading into 2024. But the drugmaker also has its sights se2024/1/9
-
JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience companyAge 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Morgan Healthcare Conference, chief operating officer Blair Jackson said in an interview. After2024/1/9
-
JPM24: Roche says rebound in hematology sparked by potential of newly approved Lunsumio, ColumviAfter Roche went through a period of declining sales in hematology—as powerhouse Rituxan faced biosimilar competition and follow-on Gazyva failed to live up to its blockbuster expectations—the compan2024/1/4
-
JPM24, Day 2: Lilly CEO says competition benefits obesity field; Novavax readies phase 3 combo trialTuesday, Jan. 9 at 8:30 p.m. ET AstraZenecalaid out its lofty goals for the end of the decade, which include not only delivering “industry-leading growth” by 2030, but placing in at least “the top-th2024/1/4
-
JPM24: Pfizer CEO promises 'year of execution' after recent struggles, Seagen buyoutPfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took,2024/1/2